KIRKLAND, Wash., April 21 -- LifeSpex Inc. and Hoya Corp. report that Hoya Holdings Inc. has made a strategic equity investment in LifeSpex Corp. LifeSpex develops bio-photonics to provide point-of-care diagnostic systems for the detection of epithelial cancers. The company will use the investment proceeds to complete pivotal clinical trials for its Cerviscan product in the United States and Europe and to establish manufacturing capacity for early production shipments.
The Cerviscan system uses Evoked Tissue Fluorescence technology to enable physicians to directly assess and locate patients' cervical precancers and cancers in an office environment. LifeSpex Corp. has over 15 issued and blocking patents and patent applications in collaboration with the University of Texas at Austin.